The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 10, 2006, Pages 1177-1179

  Bonifati, D M ^a   Witchel, S F ^b   Ermani, M ^a   Hoffman, E P ^c   Angelini, C ^a   Pegoraro, E ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c Center for Nutrition Genetics & Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; COMPLEMENTARY DNA; DEFLAZACORT; GLUCOCORTICOID RECEPTOR; PREDNISONE; SERINE; STEROID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DUCHENNE MUSCULAR DYSTROPHY; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; INCIDENCE; MOBILIZATION; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREDNISONE; PREGNENEDIONES; RECEPTORS, GLUCOCORTICOID; STEROIDS;

EID: 33748989029     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2005.078345     Document Type: Article

References (23)

1. Allsop KG, Ziter FA. Loss of strength and functional decline in Duchenne Dystrophy. Arch Neurol 1981;38:406-11.
2. Dubowitz V. The muscular dystrophies. In: Dubowitz V, ed. Muscle disorders in childhood. London, Philadelphia and Toronto: Saunders, 1995:38-48.
3. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974;2:1409-12.
4. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol 1987;44:812-17.
5. Fenichel GM, Florence J, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-7.
6. Fenichel GM, Mendell JR, Moxley RT, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991;48:575-9.
7. Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Arch Neurol 1991;48:383-8.
8. Griggs RC, Moxley RT, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43:520-7.
9. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1998;320:1592-7.
10. Moxley RT, Ashwal S, Pandya S, et al. Practice Parameter: Corticosteroid treatment of Duchenne dystrophy. Neurology 2005;64:13-20.
11. Bushby K, Muntoni F, Urtizberea A, et al. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. Neuromusc Disord 2004;14:526-34.
12. Dubrovsky AL, Angelini C, Bonifati DM, et al. Steroids in muscular dystrophy: where do we stand? Neuromuscul Disord 1998;8:380-4.
13. De Silva S, Drachman DB, Mellits D, et al. Prednisone treatment in Duchenne muscular dystrophy. Arch Neurol 1987;44:818-22.
14. Khan MA. Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci 1993;120:8-14.
15. Beato M. Gene regulation by steroid hormones. Cell 1989;56:335-44.
16. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
17. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 1995;50:317-33.
18. Angelini C, Pegoraro E, Perini F, et al. A trial with a new steroid in Duchenne muscular dystrophy. In: Angelini C, Danieli Ga, Fontanari D, eds. Muscular dystrophy research. New York: Elsevier Science Publishers, 1991:173-9.
19. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-7.
20. Karl M, Lamberts SW, Detera-Wadleigh SD, et al. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab 1993;76:683-9.
21. Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: study of long term effects. Muscle Nerve 1994;17:386-91.
22. Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the human glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998;83:144-51.
23. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996;17:245-61.